|
|
||||||||

,
,

* Department of Microbiology,
Department of Biochemistry,
Department of Cell and Developmental Biology, and
College of Medicine, University of Illinois, Urbana, IL 61801;
¶ Department of Pediatric Immunology and
|| Department of Dermatology and Venerology, Akdeniz University School of Medicine, Akdeniz University, Antalya, Turkey; and
# Institute of Microbiology and Hygiene, Charité-University Medical Center, Humboldt-University Berlin, Berlin, Germany
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
TLRs 1, 2, and 6 are a phylogenetically related subfamily. High sequence similarity and tandem arrangement of TLRs 1 and 6 in the human genome suggest that these two receptors arose from a recent gene duplication event (4, 5). TLR2 requires either TLR1 or TLR6 as a coreceptor, which confers ligand specificity and enables cell signaling (6). Collectively, these receptor pairs mediate immune responses to a wide variety of acylated cell wall components derived from Gram-positive bacteria, Gram-negative bacteria, mycoplasma, spirochetes, and fungi (1, 2). In accordance with their broad recognition capability, mice deficient in TLR2 exhibit increased susceptibility in a variety of acute infection models (7). Clinical studies have revealed associations between infectious disease and single nucleotide polymorphisms (SNPs)3 within TLR genes, highlighting the importance of these receptors in human immune defense (8, 9).
Mycobacterium leprae is the causative agent of leprosy, a chronic disease of the skin and peripheral nervous system in which an estimated 700,000 new cases are detected annually (10). The host response to M. leprae exposure is quite variable, and mounting evidence strongly suggests that a variety of host genetic factors play a role in determining the extent and severity of infection (11). M. leprae bacilli, as well as several mycobacterial cell wall components, are agonists for the TLR1/2 receptor pair, including lipomannan, lipoarabinomannan, phosphatidylinositol dimannoside, and a 19-kDa lipoprotein (12, 13, 14, 15). TLRs 1 and 2 are expressed by a variety of cell types in both the dermis and epidermis of the skin, and their expression has been detected in leprosy lesions by immunostaining (15). In this study, we report that a frequently occurring SNP in TLR1, which impairs receptor trafficking and function, plays a protective role in the context of clinical leprosy, indicating that TLR1/2 signaling during M. leprae infection may be detrimental to the host.
| Materials and Methods |
|---|
|
|
|---|
Synthetic lipopeptides were purchased from EMC Microcollections. Repurified LPS (Salmonella minnesota Re595) was purchased from List Biological Laboratories. Heat-killed Staphylococcus aureus and Acholeplasma laidlawii, as well as Porphymonas gingivalis LPS, were obtained from InvivoGen.
Cells and cell culture
Human PBMCs were isolated from the blood of healthy donors by centrifugation through a Ficoll gradient. For experiments requiring a pure monocyte population, isolation was performed by negative selection over magnetic beads (Miltenyi Biotec). Monocyte preparations were of >95% purity as determined by staining for CD14.
Flow cytometric analysis
Cell surface expression of endogenous TLR1, TLR2, and TLR6 was measured using mAbs GD2.F4, T2.5, and hPER6, respectively (eBioscience). Appropriate isotype-matched Abs were used as controls. Ab staining was followed by biotinylated secondary Ab and PE-conjugated streptavidin (Jackson ImmunoResearch Laboratories). To detect intracellular levels of TLRs, cells were fixed in PBS containing 2% (w/v) paraformaldehyde and permeabilized with 0.1% (w/v) saponin before staining.
Cell stimulation
SW620 cell and 293T cell transfections, stimulation, and data analyses were performed as described previously (16). Human PBMCs were seeded in 96-well plates at a density of 1 x 105 cells/well and stimulated with the indicated agonists for 16 h. The concentration of secreted human TNF-
was measured in the supernatant using a paired Ab TNF-
sandwich ELISA (Invitrogen Life Technologies).
Genotyping of blood donors
A fragment containing exon 4 of TLR1 was amplified from genomic DNA using the following PCR primers: forward, CTTGATCTTCACAGCAATA AAATAAAGAGCATTCC, and reverse, GGCCATGATACACTAGAACACACATCACT. PstI digestion of the product was used to discriminate between the TLR1 602 alleles. Validity of this assay was confirmed by sequencing DNA from several donors of each genotype.
Immunoblotting
Whole lysate or immunoprecipitates from transfected 293T cells were separated on a 7.5% SDS-polyacrylamide gel followed by Western blotting using either anti-FLAG M2 Ab (Sigma-Aldrich) or anti-HA.11 Ab (Covance).
Confocal microscopy
Primary monocytes were plated in chamber slides (Labtek) and allowed to adhere overnight. Cells were then washed, and one group was fixed with 2% paraformaldehyde, followed by permeabilization with 0.5% Triton X-100. Cells from the other group were untreated. After blocking FcRs, Ab staining was conducted using anti-TLR1 and a Signal Amplification kit (Molecular Probes). Images were acquired on a Zeiss LSM 510 scanning confocal laser microscope.
Leprosy samples
Leprosy patients were recruited from two main centers located in endemic areas in Turkey: Leprosy Hospital, Elazig, and Akdeniz University, Antalya. Leprosy diagnosis was based on clinical findings and laboratory tests, which usually involved either a blood smear and/or skin biopsy. M. leprae was identified by the presence of acid-fast bacilli and histopathological changes. Differential diagnoses, including granulomatous disease, syphilis, tuberculosis, sarcoidosis, and deep fungal infection, were excluded by clinical and laboratory criteria. Asymptomatic control subjects were recruited from the same centers and had neither family history nor symptoms related to leprosy. Protocols involving human subjects were approved by human subject review committees at University of Illinois, Humboldt-University Berlin, and Akdeniz University. Written informed consent was obtained from all blood draw participants, control subjects, and leprosy patients.
Genotyping of leprosy samples
Genotyping was performed on genomic DNA using fluorescence-labeled hybridization as described previously (17). The PCR contained the primers TGTGACTACCCGGAAATTATAGA and CCCAGAAAGAATCGTGCC along with the hybridization-fluorescence resonance energy transfer probes CCATGCTGGTGTTGGCTGTGACTGTG-FL and LCRed640-CCTCCCTCTGCATCTACTTGGAT. The TLR1 602I and 602S alleles gave rise to melting peaks at 64.5 and 58.3°C, respectively. The genotyping protocol was verified on several samples.
Statistical analysis
ANOVA and posthoc statistical analyses, including Fishers exact test, were performed using algorithms provided in SPSS software version 14.0.
| Results and Discussion |
|---|
|
|
|---|
Upon staining human peripheral blood monocytes for TLRs using a sensitive biotin-streptavidin protocol, we observed that TLR2 and TLR6 were readily detected. However, monocytes obtained from some blood donors completely lacked detectable cell surface of levels of TLR1 (Fig. 1A). To determine whether this reflected a complete absence of TLR1 expression, we performed flow cytometric analysis on permeabilized monocytes and found no significant difference in total TLR1 protein levels between cells that expressed surface TLR1 and cells that did not (Fig. 1A). Taken together, these results demonstrate that some individuals lack surface expression of TLR1 without exhibiting any deficiency in total cellular levels of receptor.
|
Since no defect in surface expression of the phylogenetically related TLR6 molecule was observed in any donors, this suggested that a genetic polymorphism specific to the TLR1 gene locus might underlie the lack of cell surface expression of TLR1. A search of the National Center for Biotechnology Information (NCBI) database revealed the existence of only two commonly occurring SNPs within TLR1, one of which, rs5743618, exchanges an isoleucine for a serine at amino acid position 602. This SNP was selected for further analysis as it is found at the junction of the transmembrane and intracellular domain of this receptor; a region that could affect intracellular trafficking. Additionally, amino acid sequence alignment of TLR1 from various vertebrate species revealed a highly conserved hydrophobic side chain (isoleucine, leucine, or valine) at this position that is also present in the closely related TLR6 and TLR10 receptors but is absent in TLR2 and all other TLR family members (data not shown).
We examined the cell surface expression of TLRs 1, 2, and 6 in peripheral blood monocytes obtained from 60 healthy volunteers and genotyped the blood donors with respect to the TLR1 602 allele (Fig. 2A). One-way ANOVA revealed a highly significant difference in cell surface TLR1 expression among the genotypes (p = 0.001). Posthoc statistical tests demonstrated that significantly lower cell surface levels of TLR1 are expressed by monocytes derived from individuals who are homozygous for the 602S allele in comparison to individuals who are either heterozygous (p = 0.005) or homozygous for the 602I allele (p = 0.0005). As expected, the levels of expression of either TLR2 or TLR6 were not found to be different between the three genotypes, demonstrating a lack of association between the TLR1 602 allele and cell surface levels of these related receptors (Fig. 2A).
|
release (p < 0.05) in response to Pam3CSK4. These results suggest that low cell surface levels of TLR1 impair cellular responses to this agonist (Fig. 2B). As expected, responses of monocytes to enteric bacterial LPS, an established agonist for TLR4, were not significantly different among the three genotypes. Expression and function of TLR1 602S is impaired in heterologous systems
Since it remained possible that the TLR1 602S allele was not directly responsible for the TLR1 low phenotype but was simply in linkage disequilibrium with the true allele, we introduced this SNP into a TLR1 expression vector by site directed mutagenesis. While TLR1 602I was readily detected by flow cytometry on the surface of transfected cells, the TLR1 602S variant was not (Fig. 3A). However, total cellular levels of both variants of TLR1 were equally observed as revealed by flow cytometric analysis of permeabilized cells, as well as Western blot analysis of cell lysates (Fig. 3, B and C). To assess the functional activity of the TLR1 602 variants, we used SW620 epithelial cells, a human colonic epithelial cell line that does not express either endogenous TLR1 or TLR2 and has been used to reconstitute the activity of this heterodimeric receptor pair (16). Following cotransfection with TLR2, the TLR1 602I variant mediated cellular responses to a variety of diverse agonists for this receptor pair, including a mycobacterial membrane preparation (Fig. 3D). In contrast, cells cotransfected with TLR2 along with the TLR1 602S variant did not mediate a response to any of these bacterial-derived components over that of TLR2 alone. Taken together with our previous findings, these results show that the TLR1 602S allele, and not a genetically linked allele, affects cell surface expression of this receptor as well as cellular responses to a variety of bacterial products. To our knowledge, this is the first demonstration of a TLR SNP that affects receptor trafficking.
|
TLR1 602S is a common allele in Caucasians and protects against leprosy
Due to the established importance of TLR1 in mediating recognition of mycobacterial cell wall components, we assessed the frequency of the I602S allele in a cohort of 57 Turkish leprosy patients and 90 asymptomatic control patients recruited from centers in areas where this disease is endemic. Surprisingly, we found that the 602S allele was significantly underrepresented in the leprosy patient population vs the control population with a statistically significant odds ratio of 0.48 (Table I). When we examined our data in the context of genotype frequencies, an association between the homozygous 602I genotype (p = 0.018) and leprosy was observed while a decreased incidence of leprosy was associated with the homozygous 602S genotype (p = 0.017) (Table I). Our results strongly suggest that diminished TLR1 expression and function is protective for the development of clinical leprosy, suggesting that M. leprae subverts the TLR system to evade the host immune system. In this regard, mycobacterial-induced TLR2 activation has been shown to render macrophages unresponsive to IFN-
, a cytokine that would otherwise induce phagolysosomal killing, Ag presentation, and T cell recruitment responses (23, 24). We are currently investigating whether the TLR1 602S allele protects against mycobacteria by enabling macrophages to maintain their responsiveness to IFN-
during infection.
|
A phylogenetic analysis of TLRs identified in all vertebrate species to date shows that all family members, including the subfamily comprising TLRs 1, 6, and 10, have evolved under strong purifying selection (4, 5). Genotyping reveals that 602S is the most prevalent allele found in white individuals (75% frequency), with a decreased allele frequency observed in individuals of Turkish (43%) and African descent (26%) (Table II). Overall, the data indicate that more than half of white persons are homozygous for the 602S allele. Surprisingly, all 21 donors of East Asian ancestry genotyped in our study were homozygous for the 602I allele, and the 602S allele was never observed in this group. These results suggest that, if a strong purifying selection for a particular 602 allele took place, it was restricted by either additional genetic or environmental factors, for example, specific pathogens or past epidemics that were constrained geographically. In the context of mycobacterial infection, a study of 25,000 nursing home residents revealed that African Americans were twice as likely to develop tuberculosis as Caucasians and that no identifiable social or environmental factor could account for this difference (26). This distribution is consistent with the idea that the 602I allele is a predisposing genetic factor for this disease. TLR1 I602S represents the most common SNP affecting TLR function identified in any population to date. Additional studies will be required to shed light on the biological role of this polymorphism and its evolutionary selection in the context of infectious disease and chronic inflammation.
|
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by the Deutsche Forschungsgemeinschaft (to R.S.) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Grant AI052344 (to R.I.T.). Crude membrane fraction from Mycobacterium tuberculosis was obtained from Colorado State University under National Institute of Allergy and Infectious Diseases contract N01 AI75320. ![]()
2 Address correspondence and reprint requests to Dr. Richard I. Tapping, Department of Microbiology, University of Illinois, B103 CLSL MC110, 601 South Goodwin Avenue, Urbana, IL 61801. E-mail address: tapping{at}life.uiuc.edu ![]()
3 Abbreviation used in this paper: SNP, single nucleotide polymorphism. ![]()
Received for publication March 21, 2007. Accepted for publication April 23, 2007.
| References |
|---|
|
|
|---|
by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J. Immunol. 176: 3019-3027.
-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling. J. Immunol. 176: 4323-4330. This article has been cited by other articles:
![]() |
K. Nagpal, T. S. Plantinga, J. Wong, B. G. Monks, N. J. Gay, M. G. Netea, K. A. Fitzgerald, and D. T. Golenbock A TIR Domain Variant of MyD88 Adapter-like (Mal)/TIRAP Results in Loss of MyD88 Binding and Reduced TLR2/TLR4 Signaling J. Biol. Chem., September 18, 2009; 284(38): 25742 - 25748. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer Pharmacol. Rev., June 1, 2009; 61(2): 177 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Purdue, Q. Lan, S. S. Wang, A. Kricker, I. Menashe, T.-Z. Zheng, P. Hartge, A. E. Grulich, Y. Zhang, L. M. Morton, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma Carcinogenesis, February 1, 2009; 30(2): 275 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Wurfel, A. C. Gordon, T. D. Holden, F. Radella, J. Strout, O. Kajikawa, J. T. Ruzinski, G. Rona, R. A. Black, S. Stratton, et al. Toll-like Receptor 1 Polymorphisms Affect Innate Immune Responses and Outcomes in Sepsis Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 710 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Sieling, P. J. Hill, K. M. Dobos, K. Brookman, A. M. Kuhlman, M. Fabri, S. R. Krutzik, T. H. Rea, D. G. Heaslip, J. T. Belisle, et al. Conserved Mycobacterial Lipoglycoproteins Activate TLR2 but Also Require Glycosylation for MHC Class II-Restricted T Cell Activation J. Immunol., May 1, 2008; 180(9): 5833 - 5842. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |